Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round

艾斯视觉集团宣布完成2940万美元B轮融资的初步交割

Funding supports the commercial product development of VisioLite® Device and Laser Scleral Microporation Human Clinical Study.

资金支持VisioLite®设备的商业产品开发和激光巩膜微孔人体临床研究。

Capital raised to date provides strong financial position to prepare the device for regulatory trials and submissions.

迄今为止筹集的资金为设备的监管试验和申报提供了坚实的财务基础。

BOSTON, April 24, 2025-- Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.

波士顿，2025年4月24日——Ace Vision Group, Inc（“AVG”或“公司”），一家致力于为年龄相关性视力丧失开发激光巩膜微孔术（LSM）疗法的新兴医疗设备公司，今天宣布成功完成了一轮2940万美元的B轮融资。

The new capital will support the continued development of the company’s proprietary Gen II VisioLite® Ophthalmic Laser, which delivers the minimally invasive LSM procedure — a treatment targeting the loss of Dynamic Range of Focus caused by presbyopia.

新资金将支持公司专有的第二代 VisioLite® 眼科激光器的持续开发，该激光器提供微创的 LSM 手术——一种针对因老花眼导致的动态聚焦范围丧失的治疗方法。

“This Series B funding marks a critical inflection point for our company,” said Dr. AnnMarie Hipsley, founder and CEO of Ace Vision Group. “It enables us to finalize the research and design of our commercial system and positions us to initiate clinical trials both in the U.S. and internationally. We remain on track to submit our 510(k) application in 2026.”.

“这笔B轮融资标志着我们公司的一个关键转折点，”Ace Vision Group创始人兼首席执行官AnnMarie Hipsley博士说道。“它使我们能够完成商业系统的研究和设计，并为我们在美国和国际上启动临床试验做好准备。我们仍然有望在2026年提交510(k)申请。”

The investment round was led by a syndicate of prominent eye care investors, underscoring strong market validation for a safe, office-based procedure that addresses the underlying biomechanical cause of presbyopia. “Presbyopia affects over 2.1 billion people globally, representing one of the most common, yet underserved, conditions in vision care” emphasized Dr.

本轮融资由一批著名的眼科护理投资者组成的财团领投，充分证明了市场对这种安全的、基于诊所的程序的高度认可，该程序解决了老花眼的根本生物力学原因。Dr.强调：“老花眼影响着全球超过21亿人，是视力护理中最常见但服务不足的病症之一。”

Hipsley..

希普斯利..

Ace Vision Group’s patented LSM technology aims to become the first laser-based, in-office therapeutic designed to treat progressive presbyopia by reducing age-related ocular rigidity – the root cause of presbyopia. In a recent pilot study using a Gen I device, the procedure showed encouraging outcomes, with a majority of patients no longer requiring reading glasses after treatment.

Ace Vision Group的专利LSM技术旨在成为首个基于激光的、在办公室内进行的治疗方案，通过减少与年龄相关的眼部僵硬（老花眼的根本原因）来治疗进行性老花眼。在最近使用第一代设备进行的试点研究中，该程序显示出令人鼓舞的结果，大多数患者在接受治疗后不再需要阅读眼镜。

“This technology resonates deeply with both physicians and patients because blurry near vision isn’t just common – it’s inevitable with age,” said Dr. Hipsley..

“这项技术引起了医生和患者的强烈共鸣，因为随着年龄的增长，近视力模糊不仅是常见的问题，更是不可避免的，”希普斯利博士说道。

“There is a clear and growing demand for in-office, ultra-minimally invasive solutions that address the root cause of presbyopia while preserving patient convenience and clinical efficiency. AVG’s technology aligns directly with this unmet need, offering a scalable, procedure-based model that integrates seamlessly into ophthalmic practices.

“市场对于在办公室内进行的、超微创的解决方案的需求日益增长，这些方案需要解决老花眼的根本原因，同时兼顾患者的便利性和临床效率。AVG的技术正好符合这一未满足的需求，提供了一种可扩展的、基于程序的模型，能够无缝整合到眼科实践中。”

This level of market relatability, combined with strong clinical interest and favorable economics, positions us for broad adoption and long-term value creation,” added Dr. Hipsley..

“这种与市场的高度关联性，加上强烈的临床兴趣和有利的经济因素，为我们实现广泛采用和长期价值创造奠定了基础，”Hipsley 博士补充道。

About Ace Vision Group

关于Ace Vision集团

Ace Vision Group, Inc. (AVG) is a privately held U.S. ophthalmic medical device company developing Laser Microporation Therapeutic technologies to address age-related eye dysfunction and address the eye's natural biomechanical performance. AVG's Laser Scleral Microporation (LSM) is a therapeutic eye laser treatment that aims to restore visual function naturally without sacrificing distance vision.

Ace Vision Group, Inc.（AVG）是一家私营的美国眼科医疗器械公司，致力于开发激光微孔治疗技术，以应对与年龄相关的眼部功能障碍，并改善眼睛的自然生物力学性能。AVG的激光巩膜微孔（LSM）是一种治疗性眼部激光疗法，旨在自然恢复视觉功能，同时不牺牲远视力。

AVG's brand promise is to provide the field of ophthalmology with innovative devices, Microporation Therapeutic procedures, and education for the treatment of age-related ocular dysfunction, disability, and disease. For more information about Ace Vision Group please visit www.acevisiongroup.com..

AVG的品牌承诺是为眼科领域提供创新设备、微孔治疗程序以及针对与年龄相关的眼部功能障碍、残疾和疾病的治疗教育。有关Ace Vision Group的更多信息，请访问www.acevisiongroup.com。

Contact:

联系人：

Investor and Media Contacts

投资者和媒体联系人

Nicholas Perrin

尼古拉斯·佩兰

nperrin@acevisiongroup.com

nperrin@acevisiongroup.com

Taylor Steiner

泰勒·施泰纳

taylor.steiner@precisionaq.com

泰勒·施泰纳@精密AQ.com